Bellevue Asset Management »

Ptc Therapeutics I shares owned by Bellevue Asset Management

Quarter-by-quarter ownership of Ptc Therapeutics I (PTCT) shares owned by Bellevue Asset Management from 13F filings

Historical chart of Bellevue Asset Management investment in Ptc Therapeutics I

Tip: Access up to 7 years of quarterly data

All positions including Ptc Therapeutics I held by Bellevue Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Ptc Therapeutics I by Bellevue Asset Management

Quarter filed Position value Share count Share price at filing
2015-12-31 $1.8M 55k 32.40

More positions owned by Bellevue Asset Management

Celgene Corporation
Biogen Idec (BIIB)
Gilead Sciences (GILD)
Amgen (AMGN)
Regeneron Pharmaceuticals (REGN)
Medtronic
Illumina (ILMN)
Abbott Laboratories (ABT)
Mylan
Becton, Dickinson and (BDX)
Cardinal Health (CAH)
UnitedHealth (UNH)
Stryker Corporation (SYK)
Teva Pharmaceutical Industries (TEVA)
Express Scripts Holding

View all positions for Bellevue Asset Management

Top funds holding Ptc Therapeutics I

Wellington Management Company
Vanguard Group
Cowen And Company
Henderson Group
Franklin Resources
D. E. Shaw & Co
Jacobs Levy Equity Management
Blackstone Group
T. Rowe Price Associates
Tang Capital Management
Voloridge Investment Management
Jane Street
Jpmorgan Chase & Co
Charles Schwab Investment Management
Norges Bank Investment Management

View all funds holding Ptc Therapeutics I